Aclaris Therapeutics (ACRS) Shares Outstanding (Weighted Average) (2017 - 2025)
Historic Shares Outstanding (Weighted Average) for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $122.6 million.
- Aclaris Therapeutics' Shares Outstanding (Weighted Average) rose 7177.97% to $122.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.6 million, marking a year-over-year increase of 7177.97%. This contributed to the annual value of $77.3 million for FY2024, which is 1072.62% up from last year.
- Per Aclaris Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $122.6 million for Q3 2025, which was up 7177.97% from $122.6 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $122.6 million in Q3 2025 and a low of $50.3 million during Q1 2021
- In the last 5 years, Aclaris Therapeutics' Shares Outstanding (Weighted Average) had a median value of $69.8 million in 2023 and averaged $74.6 million.
- Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first skyrocketed by 81.04% in 2024, then soared by 7219.92% in 2025.
- Over the past 5 years, Aclaris Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $56.7 million in 2021, then increased by 14.95% to $65.2 million in 2022, then grew by 7.05% to $69.8 million in 2023, then grew by 10.73% to $77.3 million in 2024, then surged by 58.63% to $122.6 million in 2025.
- Its Shares Outstanding (Weighted Average) stands at $122.6 million for Q3 2025, versus $122.6 million for Q2 2025 and $122.4 million for Q1 2025.